Denmark, Norway and Iceland have entered into cooperation regarding the procurement of pharmaceuticals. The countries will jointly procure and award framework agreements in order to ensure the supply of pharmaceuticals in the countries. A framework agreement will cover delivery of the pharmaceuticals in all three countries. However, for the lot numbers 1-3 the supplier shall only deliver the pharmaceuticals to Denmark and Norway. In Denmark certain pharmaceuticals are resold to the Faroe Island and Greenland. The obligation to deliver the pharmaceuticals in Iceland is subject to the precondition that the supplier obtains an exemption regarding printed labels and leaflets. If the supplier does not obtain such exemption the agreement will only apply to Denmark and Norway, see the Framework agreement section 2.2.1 and Appendix 6.

Lot. no. 1

The following pharmaceuticals are included in the lot number: ATC Code: L01AB02 · Generic name: Treosulfan (DK/NO) · Pharmaceutical form: Powder f. infusion fluid · Strength: 1 g · Unit: 10 g ··· ATC Code: L01AB02 · Generic name: Treosulfan (DK/NO) · Pharmaceutical form: Powder f. infusion fluid · Strength: 5 g · Unit: 10 g. Under the title "Quantity in units" listed in the List of Products (Appendix A), an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Lot. no. 2

The following pharmaceuticals are included in the lot number: ATC Code: L01BB04 · Generic name: Cladribin (DK/NO) · Pharmaceutical form: Injection Fluid · Strength: 2 mg/ml · Unit: 6,3 mg. Under the title "Quantity in units" listed in the List of Products (Appendix A), an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Lot. no. 3

The following pharmaceuticals are included in the lot number: ATC Code: L01CA05 · Generic name: Vinflunin (DK/NO) · Pharmaceutical form: Conc. Infusion fluid · Strength: 25 mg/ml · Pack size: 2 ml · Unit: 500 mg ··· ATC Code: L01CA05 · Generic name: Vinflunin (DK/NO) · Pharmaceutical form: Conc. Infusion fluid · Strength: 25 mg/ml · Pack size: 10 ml · Unit: 500 mg. Under the title "Quantity in units" listed in the List of Products (Appendix A), an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Lot. no. 4

The following pharmaceuticals are included in the lot number: ATC Code: L01BA01 · Generic name: Methotrexat (DK/IS/NO) · Pharmaceutical form: Injection Fluid · Strength: 25 mg/ml · Unit: 11,429 mg. Under the title "Quantity in units" listed in the List of Products (Appendix A), an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Lot. no. 5

The following pharmaceuticals are included in the lot number: ATC Code: L01BC01 · Generic name: Cytarabin (DK/IS/NO) · Pharmaceutical form: Injection and Infusion fluid · Strength: 20 mg/ml · Unit: 500 mg. Under the title "Quantity in units" listed in the List of Products (Appendix A), an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Lot. no. 6

The following pharmaceuticals are included in the lot number: ATC Code: L01BC01 · Generic name: Cytarabin (DK/IS/NO) · Pharmaceutical form: Injection and Infusion fluid · Strength: 100 mg/ml · Pack size: 10 ml · Unit: 500 mg ··· ATC Code: L01BC01 · Generic name: Cytarabin (DK/IS/NO) · Pharmaceutical form: Injection and Infusion fluid · Strength: 100 mg/ml · Pack size: 20 ml · Unit: 500 mg. Under the title "Quantity in units" listed in the List of Products (Appendix A), an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Lot. no. 7

The following pharmaceuticals are included in the lot number: ATC Code: L01CA02 · Generic name: Vincristin (DK/IS/NO) · Pharmaceutical form: Injection Fluid · Strength: 1 mg/ml · Pack size: 2 ml · Unit: 2 mg. Under the title "Quantity in units" listed in the List of Products (Appendix A), an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Lot. no. 8

The following pharmaceuticals are included in the lot number: ATC Code: L01CE01 · Generic name: Topotecan (DK/IS/NO) · Pharmaceutical form: Conc. Infusion fluid · Strength: 1 mg/ml · Pack size: 4 ml · Unit: 2 mg. Under the title "Quantity in units" listed in the List of Products (Appendix A), an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Lot. no. 9

The following pharmaceuticals are included in the lot number: ATC Code: L01CX01 · Generic name: Trabectedin (DK/IS/NO) · Pharmaceutical form: powder f.conc.f.inf.fluid · Strength: 0,25 mg/dose · Unit: 2,5 mg ··· ATC Code: L01CX01 · Generic name: Trabectedin (DK/IS/NO) · Pharmaceutical form: powder f.conc.f.inf.fluid · Strength: 1 mg/dose · Unit: 2,5 mg. Under the title "Quantity in units" listed in the List of Products (Appendix A), an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Lot. no. 10

The following pharmaceuticals are included in the lot number: ATC Code: L01DB02 · Generic name: Daunorubicin (DK/IS/NO) · Pharmaceutical form: Powder f. infusion fluid · Strength: 20 mg · Unit: 80 mg. Under the title "Quantity in units" listed in the List of Products (Appendix A), an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Lot. no. 11

The following pharmaceuticals are included in the lot number: ATC Code: L01DB03 · Generic name: Epirubicin (DK/IS/NO) · Pharmaceutical form: Injection and Infusion fluid · Strength: 2 mg/ml · Pack size: 25 ml · Unit: 100 mg ··· ATC Code: L01DB03 · Generic name: Epirubicin (DK/IS/NO) · Pharmaceutical form: Injection and Infusion fluid · Strength: 2 mg/ml · Pack size: 50-100 ml · Unit: 100 mg. Under the title "Quantity in units" listed in the List of Products (Appendix A), an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Lot. no. 12

The following pharmaceuticals are included in the lot number: ATC Code: L01DB06 · Generic name: Idarubicin (DK/IS/NO) · Pharmaceutical form: Injection Fluid · Strength: 5 mg · Unit: 20 mg ··· ATC Code: L01DB06 · Generic name: Idarubicin (DK/IS/NO) · Pharmaceutical form: Injection Fluid · Strength: 10 mg · Unit: 20 mg. Under the title "Quantity in units" listed in the List of Products (Appendix A), an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Lot. no. 13

The following pharmaceuticals are included in the lot number: ATC Code: L01XX27 · Generic name: Arsentrioxid (DK/IS/NO) · Pharmaceutical form: Conc. Infusion fluid · Strength: 1-2 mg/ml · Unit: 7,5 mg. Under the title "Quantity in units" listed in the List of Products (Appendix A), an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Lot. no. 14

The following pharmaceuticals are included in the lot number: ATC Code: L01AA09 · Generic name: Bendamustin (DK/IS/NO) · Pharmaceutical form: powder f.conc.f.inf.fluid · Strength: 25 mg · Unit: 200 mg ··· ATC Code: L01AA09 · Generic name: Bendamustin (DK/IS/NO) · Pharmaceutical form: powder f.conc.f.inf.fluid · Strength: 100 mg · Unit: 200 mg. Under the title "Quantity in units" listed in the List of Products (Appendix A), an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.